canada semaglutide patent Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs Novo Nordisk lets key Ozempic

Some individuals may experience weight loss during the initial months of treatment, which may be related to nausea and decreased appetite

Journal of Neurophysiology, 2005

(2013) 8:e61217

None of this changes the established safety profile of these medications, but it does underscore the value of listening to patient experience and taking unexplained symptoms seriously

Use only with physician supervision

Clinical study demonstrating that acute GLP-1 infusion reduces glomerular hyperfiltration and produces an increase in urinary sodium excretion and a decrease in urinary hydrogen excretion in insulin-resistant obese men